4T1 Mouse Model
Breast cancer is the second most common cancer that is diagnosed in women in the United States; treatments in early stage diagnosis are well established, but therapeutics for treating advanced metastatic variations remain limited. 4T1 cells most closely mimic triple-negative breast cancer (TNBC) which is responsible for over 17% of breast cancer worldwide per year and thus serve as the ideal model for preclinical TNBC studies.
4T1 is highly tumorigenic, highly invasive and spontaneously metastasized from the primary tumor site. It can be used in orthotopic and flank models for study of primary tumors and for late-stage metastatic disease. Our models are fully characterized and can be adapted to suit the needs of your study.
Metastatic potential
This cell line spontaneously metastasizes in mice, spreading to the lung, liver, lymph nodes, brain, and bone, providing a viable platform for late-stage drug discovery.
Fully Characterized Model
We have characterized 4T1 mouse mammary gland cancer expressed as a flank model in BALB/c or in immunocompromised mice.
4T1 Syngeneic Breast Cancer Model
The 4T1 cell line is a triple-negative transplantable mammary carcinoma that has many applications in the drug-discovery pipeline.
Breast cancer derived cell line from the mammary gland tissue of BALB/c mice. This epithelial cell line resembles human triple-negative breast cancer (TNBC) with the lack of expression of ER, PR, and HER2.
Very closely related in tumor growth and metastatic spread to that of human breast cancer, Stage IV. Carrying a resistance to 6-thioguanine and ChEBI, metastatic cells can be detected in other distant site organs with good accuracy.
For stage IV breast cancer, the standard of care is systemic drug therapies such as hormone therapy, chemotherapy, targeted drugs, immunotherapy and a combination of these. In some instances surgery and radiation therapy may be useful.